L3VLUP
ProSign in

GRFS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GRFSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GRFS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterGRFSVRTX
Q3 20208 holders, $472m31 holders, $21.9bn
Q4 20207 holders, $477m30 holders, $18.4bn
Q1 20217 holders, $471m31 holders, $15.4bn
Q2 20216 holders, $442m30 holders, $12.7bn
Q3 20216 holders, $357m35 holders, $10.1bn
Q4 20215 holders, $301m28 holders, $12.4bn
Q1 20224 holders, $281m23 holders, $16.1bn
Q2 20225 holders, $406m25 holders, $18.1bn
Q3 20224 holders, $162m22 holders, $18.4bn
Q4 20224 holders, $304m28 holders, $18.4bn
Q1 20234 holders, $294m26 holders, $21.4bn
Q2 20235 holders, $391m27 holders, $24.7bn
Q3 20235 holders, $404m33 holders, $24.3bn
Q4 20235 holders, $510m32 holders, $28.6bn
Q1 20245 holders, $266m31 holders, $29.8bn
Q2 20245 holders, $249m29 holders, $33.4bn
Q3 20246 holders, $320m27 holders, $33.5bn
Q4 20243 holders, $185m26 holders, $28.5bn
Q1 20253 holders, $178m21 holders, $35.4bn
Q2 20255 holders, $341m21 holders, $32.3bn
Q3 20254 holders, $290m22 holders, $25.9bn
Q4 20253 holders, $240m26 holders, $31.8bn
Q1 20263 holders, $199m25 holders, $31.8bn
Q2 20261 holders, $162m26 holders, $34.6bn
GRFS

Grifols SA

Holders
3
Reported value
$199m
Buyers
3
Sellers
9

Breadth -6 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GRFS (2)

Farallon Capital Management LLC, Harris Associates LP

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →